Diabetes drugs cleared of vascular harm
Two studies suggest that neither sulfonylureas nor sitagliptin increase the risk of adverse cardiovascular outcomes in patients with Type 2 diabetes.
Source: MedWire News - Category: Consumer Health News Tags: Diabetes Source Type: news
More News: Cardiology | Cardiovascular | Diabetes | Diabetes Type 2 | Endocrinology | Health | Heart | Januvia | Study